MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration

Профиль экспрессии микроРНК позволяет дифференцировать доброкачественные узлы от папиллярных карцином щитовидной железы по клеткам, полученным при тонкоигольной аспирации
Giuseppina De Marco, Aldo Pinchera, Antonio Candelieri, Paolo Vitti, Teresa Rago, Massimo Tonacchera, Patrizia Agretti, Eleonora Ferrarini, Antonio Dimida, Filippo Niccolai, Angelo Molinaro, G. Di Coscio
2012-06-24

BRAF V600E mutationfine-needle aspirationmicroRNA expression profilingpapillary thyroid carcinomaquantitative RT-PCR
OBJECTIVE: MicroRNAs (miRNAs) are small endogenous noncoding RNAs that pair with target messengers regulating gene expression. Changes in miRNA levels occur in thyroid cancer. Fine-needle aspiration (FNA) with cytological evaluation is the most reliable tool for malignancy prediction in thyroid nodules, but cytological diagnosis remains undetermined for 20% of nodules. DESIGN: In this study, we evaluated the expression of seven miRNAs in benign nodules, papillary thyroid carcinomas (PTCs), and undetermined nodules at FNA. METHODS: The prospective study included 141 samples obtained by FNA of thyroid nodules from 138 patients. miRNA expression was evaluated by quantitative RT-PCR and statistical analysis of data was performed. Genetic analysis of codon 600 of BRAF gene was also performed. RESULTS: Using data mining techniques, we obtained a criterion to classify a nodule as benign or malignant on the basis of miRNA expression. The decision model based on the expression of miR-146b, miR-155, and miR-221 was valid for 86/88 nodules with determined cytology (97.73%), and adopting cross-validation techniques we obtained a reliability of 78.41%. The prediction was valid for 31/53 undetermined nodules with 16 false-positive and six false-negative predictions. The mutated form V600E of BRAF gene was demonstrated in 19/43 PTCs and in 1/53 undetermined nodules. CONCLUSIONS: The expression profiles of three miRNAs allowed us to distinguish benign from PTC starting from FNA. When the assay was applied to discriminate thyroid nodules with undetermined cytology, a low sensitivity and specificity despite the low number of false-negative predictions was obtained, limiting the practical interest of the method.
1
A three-miRNA model using miR-146b, miR-155, and miR-221 distinguished benign nodules from papillary thyroid carcinomas using fine-needle aspiration samples.
2
Application to 53 cytologically undetermined nodules produced 31 valid predictions, with 16 false positives and six false negatives.
3
BRAF V600E was detected in 19 of 43 papillary thyroid carcinomas and one of 53 undetermined nodules; limited sensitivity and specificity reduced the method’s practical utility for indeterminate nodules.
4
Cross-validation estimated the reliability of the miRNA classification model at 78.41%.
5
The miRNA-based decision model correctly classified 86 of 88 nodules with determined cytology, corresponding to 97.73% validity.

Thyroid nodules, including benign nodules, papillary thyroid carcinomas, and nodules with undetermined cytology, sampled by fine-needle aspiration

MicroRNA expression profiles—particularly miR-146b, miR-155, and miR-221—as markers for distinguishing benign nodules from papillary thyroid carcinomas and classifying cytologically undetermined nodules

Publication Details
Publication Date
2012-06-24
Journal
Publisher
ISSN
Cited by
70
Access Type
Author Information
Authors
Giuseppina De Marco
Aldo Pinchera
Antonio Candelieri
Paolo Vitti
Teresa Rago
Massimo Tonacchera
Patrizia Agretti
Eleonora Ferrarini
Antonio Dimida
Filippo Niccolai
Angelo Molinaro
G. Di Coscio
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%